Our 2025 Year in Review is here! It was a truly monumental year for GSD1b: we launched a multi‑year international prospective natural history study, funded multiple research studies (including mannose and Glycosade), expanded our global patient contact registry, and raised over $430,000 to keep research moving forward— just to name a few highlights.
As we head into 2026, the goal is clear: build on this momentum and turn this forward motion into better treatments and quality of life for everyone living with GSD1b. Take a look at what we achieved together in 2025 and stay with us for the year ahead!